NiKang Therapeutics Initiates Study of NKT5097 in Advanced Solid Tumors
NiKang Therapeutics is conducting a dose escalation study of NKT5097 in adults with advanced/metastatic solid tumors, focusing on safety and tolerability.
Company
Pharmaceutical intelligence for NiKang Therapeutics with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.